imCare Biotech
Doylestown, US · Pennsylvania corporation
ImCare Biotech is a biotechnology company focused on research and product development aimed at delivering commercial products derived from its science.
Biotech
Founders & leadership
FY
Felix Y. LuDirector
AL
Aaron LuExecutive Officer, Director
XL
Xuanyong Lu, PhDExecutive Officer, Director
Reported raises · per SEC filings
Form D private placements▶$153.4KraisedJul 2023 · 1 investors · BiotechnologyRule 506(b)
▶$153.4KraisedJul 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank FischerDirector
- Matthew LeeDirector
- Aaron LuExecutive Officer, Director
- Xuanyong Lu, PhDExecutive Officer, Director
- Felix Y. LuExecutive Officer, Director
- Offering amount
- $153.4K
- Amount sold
- $153.4K
- First sale
- Jul 2023
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$368.4KraisedApr 2022 · 1 investors · BiotechnologyRule 506(b)
▶$368.4KraisedApr 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xuanyong Lu, PhDDirector
- Felix Y. LuDirector
- Aaron LuExecutive Officer, Director
- Offering amount
- $368.4K
- Amount sold
- $368.4K
- First sale
- Apr 2022
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$1.3MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron LuExecutive Officer, Director
- Felix Y. LuDirector
- Xuanyong Lu, PhDExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Proceeds to insiders
- $200K
- First sale
- Jul 2021
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$1.8MraisedMay 2021 · 4 investors · BiotechnologyRule 506(b)
▶$1.8MraisedMay 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felix Y. LuDirector
- Aaron LuExecutive Officer, Director
- Xuanyong Lu, PhDExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Proceeds to insiders
- $450K
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$680.1KraisedMar 2020 · 3 investors · BiotechnologyRule 506(b)
▶$680.1KraisedMar 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron Yefei LuExecutive Officer, Director
- Felix Y. LuDirector
- Lizhu TangDirector
- Xuanyong LuExecutive Officer, Director
- Offering amount
- $680.1K
- Amount sold
- $680.1K
- Proceeds to insiders
- $50K
- First sale
- Mar 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $166.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $292.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.